A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer

Project: Research

Project Details

Project Description


StatusActive
Effective start/end date20/03/2420/03/26

Keywords

  • clinical trial
  • biochemical recurrence
  • prostate cancer
  • androgen deprivation therapy